|
1
|
Beiki O, Hall P, Ekbom A and Moradi T:
Breast cancer incidence and case fatality among 4.7 million women
in relation to social and ethnic background: a population-based
cohort study. Breast Cancer Res. 14:1–13. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Malfettone A, Saponaro C, Paradiso A,
Simone G and Mangia A: Peritumoral vascular invasion and NHERF1
expression define an immunophenotype of grade 2 invasive breast
cancer associated with poor prognosis. BMC Cancer. 12:106–117.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Cowin P and Welch DR: Breast cancer
progression: controversies and consensus in the molecular
mechanisms of metastasis and EMT. J Mammary Gland Biol Neoplasia.
12:99–102. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Moreno-Bueno G, Portillo F and Cano A:
Transcriptional regulation of cell polarity in EMT and cancer.
Oncogene. 27:6958–6969. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Creighton CJ, Chang JC and Rosen JM:
Epithelial-mesenchymal transition (EMT) in tumor-initiating cells
and its clinical implications in breast cancer. J Mammary Gland
Biol Neoplasia. 15:253–260. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Vuoriluoto K, Haugen H and Kiviluoto S:
Vimentin regulates EMT induction by Slug and oncogenic H-Ras and
migration by governing Axl expression in breast cancer. Oncogene.
30:1436–1448. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Hardy KM, Booth BW, Hendrix MJ, Salomon DS
and Strizzi L: ErbB/EGF signaling and EMT in mammary development
and breast cancer. J Mammary Gland Biol Neoplasia. 15:191–199.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Vincan E and Barker N: The upstream
components of the Wnt signalling pathway in the dynamic EMT and MET
associated with colorectal cancer progression. Clin Exp Metastasis.
25:657–663. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Javle MM, Gibbs JF and Iwata KK:
Epithelial-mesenchymal transition (EMT) and activated extracellular
signal-regulated kinase (p-Erk) in surgically resected pancreatic
cancer. Ann Surg Oncol. 14:3527–3533. 2007. View Article : Google Scholar
|
|
10
|
Yin T, Wang C, Liu T, Zhao G and Zhou F:
Implication of EMT induced by TGF-beta1 in pancreatic cancer. J
Huazhong Univ Sci Technolog Med Sci. 26:700–702. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Naithani R, Huma LC, Moriarty RM,
McCormick DL and Mehta RG: Comprehensive review of cancer
chemopreventive agents evaluated in experimental carcinogenesis
models and clinical trials. Curr Med Chem. 15:1044–1071. 2008.
View Article : Google Scholar
|
|
12
|
Verschoyle RD, Steward WP and Gescher AJ:
Putative cancer chemopreventive agents of dietary origin - how safe
are they? Nutr Cancer. 59:152–162. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Basnet P and Skalko-Basnet N: Curcumin: an
anti-inflammatory molecule from a curry spice on the path to cancer
treatment. Molecules. 16:4567–4598. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Shehzad A, Wahid F and Lee YS: Curcumin in
cancer chemoprevention: molecular targets, pharmacokinetics,
bioavailability, and clinical trials. Arch Pharm. 343:489–499.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Jagtap S, Meganathan K, Wagh V, Winkler J,
Hescheler J and Sachinidis A: Chemoprotective mechanism of the
natural compounds, epigallocatechin-3-o-gallate, quercetin and
curcumin against cancer and cardiovascular diseases. Curr Med Chem.
16:1451–1462. 2009. View Article : Google Scholar
|
|
16
|
Notarbartolo M, Poma P, Perri D, Dusonchet
L, Cervello M and D’Alessandro N: Antitumor effects of curcumin,
alone or in combination with cisplatin or doxorubicin, on human
hepatic cancer cells. Cancer Lett. 224:53–65. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Chua HL, Bhat-Nakshatri P, Clare SE,
Morimiya A, Badve S and Nakshatri H: NF-kappaB represses E-cadherin
expression and enhances epithelial to mesenchymal transition of
mammary epithelial cells: potential involvement of ZEB-1 and ZEB-2.
Oncogene. 26:711–724. 2007. View Article : Google Scholar
|
|
18
|
Mulholland DJ, Kobayashi N and Ruscetti M:
Pten loss and RAS/MAPK activation cooperate to promote EMT and
metastasis initiated from prostate cancer stem/progenitor cells.
Cancer Res. 72:1878–1889. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Chen MC, Chang WW, Kuan YD, Lin ST, Hsu HC
and Lee CH: Resveratrol inhibits LPS-induced epithelial-mesenchymal
transition in mouse melanoma model. Innate Immun. 32:1–9.
2012.PubMed/NCBI
|
|
20
|
Takata M, Maniwa Y and Doi T:
Double-layered collagen gel hemisphere for cell invasion assay:
successful visualization and quantification of cell invasion
activity. Cell Commun Adhes. 14:157–167. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Tiwari N, Gheldof A, Tatari M and
Christofori G: EMT as the ultimate survival mechanism of cancer
cells. Semin Cancer Biol. 22:194–207. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Bachmeier BE, Mohrenz IV and Mirisola V:
Curcumin downregulates the inflammatory cytokines CXCL1 and -2 in
breast cancer cells via NFkappaB. Carcinogenesis. 29:779–789. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Kim HI, Huang H, Cheepala S, Huang S and
Chung J: Curcumin inhibition of integrin (alpha6beta4)-dependent
breast cancer cell motility and invasion. Cancer Prev Res (Phila).
1:385–391. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Lin SS, Lai KC, Hsu SC, et al: Curcumin
inhibits the migration and invasion of human A549 lung cancer cells
through the inhibition of matrix metalloproteinase-2 and -9 and
vascular endothelial growth factor (VEGF). Cancer Lett.
285:127–133. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Dolcet X, Llobet D, Pallares J and
Matias-Guiu X: NF-κB in development and progression of human
cancer. Virchows Arch. 446:475–482. 2005.
|
|
26
|
Giuliani C, Napolitano G, Bucci I, Montani
V and Monaco F: NF-κB transcription factor: role in the
pathogenesis of inflammatory, autoimmune, and neoplastic diseases
and therapy implications. Clin Ter. 152:249–253. 2001.(In
Italian).
|
|
27
|
Baud V and Jacque E: The alternative NF-κB
activation pathway and cancer: friend or foe? Med Sci.
24:1083–1088. 2008.(In French).
|
|
28
|
Min C, Eddy SF, Sherr DH and Sonenshein
GE: NF-kappaB and epithelial to mesenchymal transition of cancer. J
Cell Biochem. 104:733–744. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Pinho SS, Oliveira P and Cabral J: Loss
and recovery of Mgat3 and GnT-III mediated E-cadherin
N-glycosylation is a mechanism involved in epithelial-mesenchymal
transitions. PLoS One. 7:e331912012. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Ivaska J: Vimentin: Central hub in EMT
induction? Small GTPases. 2:51–53. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Wu Y and Zhou BP: Snail: More than EMT.
Cell Adh Migr. 4:199–203. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Fendrich V, Waldmann J and Feldmann G:
Unique expression pattern of the EMT markers Snail, Twist and
E-cadherin in benign and malignant parathyroid neoplasia. Eur J
Endocrinol. 160:695–703. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Shankar S, Nall D and Tang SN: Resveratrol
inhibits pancreatic cancer stem cell characteristics in human and
KrasG12D transgenic mice by inhibiting pluripotency maintaining
factors and epithelial-mesenchymal transition. PLoS One.
6:e165302011. View Article : Google Scholar
|
|
34
|
Vergara D, Valente CM and Tinelli A:
Resveratrol inhibits the epidermal growth factor-induced epithelial
mesenchymal transition in MCF-7 cells. Cancer Lett. 310:1–8. 2011.
View Article : Google Scholar : PubMed/NCBI
|
